Early [¹8F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.
Pediatr Hematol Oncol
; 27(8): 650-7, 2010 Nov.
Article
em En
| MEDLINE
| ID: mdl-20863157
ABSTRACT
The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vimblastina
/
Doença de Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Fluordesoxiglucose F18
/
Desoxicitidina
/
Tomografia por Emissão de Pósitrons
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article